November 11, 2021
ISR Vaccine AB signs collaboration agreement with Icosagen for vaccine pipelineSR Vaccine AB, a subsidiary of ISR Immune System Regulation Holding (publ), has today signed a collaboration agreement with Icosagen, Estonia, as a natural continuation of the MoU that was previously signed.
With this contract, ISR secures the company's vaccine pipeline with the development of vaccine targets for not only variants of SARS-CoV-2 but also vaccine targets for other respiratory viruses such as influenza and RSV.
“As part of building up the vaccine company, the agreement with Icosagen gives us the platform to be able to quickly adapt vaccines to SARS-CoV-2 variants and the opportunity to develop vaccines against other respiratory viruses. In collaboration with the competent team from Icosagen, we can take a place as a player in the vaccine market with our unique structure of vaccine for inhalation ", comments Ola Winqvist, CEO of ISR.
”I really hope that this will pave fruitful collaboration in SARS-CoV-2 vaccine development and also have an impact for the future efforts to make major contribution to protecting human life,” comments Mart Ustav PhD , Professor, CEO of Icosagen Group.
For more information, please contact:
Mart Ustav, Founder and CEO of Icosagen
phone: +372 522 5418